[1] Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. DOI:
10.1056/NEJMoa1607141[2] Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018 Oct;71:70-80. DOI:
10.1016/j.npep.2018.07.003[3] Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284. DOI:
10.1007/s40265-018-0871-0
